London, UK, 18 September 2023

ReNeuron Group (RENE): A step forward on the Exosome delivery platform

ReNeuron Group has generated in vivo data for CustomEX, marking a key step towards validating its proprietary stem cell-derived exosome platform. While the precise nature of the data is yet to be disclosed, we view the update as an encouraging sign and believe that it could improve traction for discussions for collaborations and partnerships, a key near-term goal for the company. ReNeuron now aims to broaden its capabilities by focussing on the functional delivery of specific therapeutics payloads, which we believe could include siRNA, mRNA, proteins, small molecules and genes, based on previous studies. Updates are expected in due course, potentially representing an important catalyst for investor attention, provided the data continue to be positive.

ReNeuron has previously reported several proof-of-concept studies exemplifying in vitro (outside of a biological setting) targeting and delivery for all seven of its exosome populations. Further details can be found in our prior update note. Now, ReNeuron has announced the successful generation of in vivo (within a biological setting, ie in animals) data, demonstrating the organ and cellular targeting capabilities of its stem cell-derived exosomes. We believe this announcement is positive for the progress of ReNeuron’s CustonEx platform. The company now plans to focus its research efforts on the functional delivery of specific payloads and management will provide a further update in the near-term. This could facilitate discussions with potential partners and hence represent an important catalyst for the company, in our view, provided the data continue to be supportive.

  
Click here to view the full report.

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached – across institutions, family offices, wealth managers and retail investors – Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first company in-market 17 years ago, Edison has more than 100 employees and covers every economic sector. Headquartered in London, Edison also has offices in New York, Sydney and Wellington.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Dr Arron Aatkar +44 (0)20 3077 5700 healtcare@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn www.linkedin.com/company/edison-group-/

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv